This Wednesday, June 8, in Dijon, Professor Sylvain Ladoire presented a new method of fighting cancer, presented at a conference in Chicago.
The Georges-François Leclerc Center presented the latest medical advances presented at the recent American Society of Clinical Oncology (ASCO) in Chicago. It was with a standing ovation that the presentation of the results of the Destiny – Breast 04 study was welcomed.
This study demonstrated the effectiveness of an antibody against the HER2 cell in patients with breast cancer. The antibody will act like a Trojan to directly attack the cancer cells by delivering a dose of chemotherapy.
The press conference of the Georges-François Leclerc Center took place this Wednesday, June 8, 2022 in the presence of Dr. Jean David Fumet, Dr. Alice Hervieu, Dr. Leïla Bengrine-Lefevre and Professor Charles Coutant and Professor Sylvain Ladoire .
© Photos Manon Bollery
Professor Sylvain Ladoire
“It simply came to our notice then. We are in a change of era. »
“There was an antibody-based therapeutic trial study”
“We’ve talked a lot about immunotherapy in recent years, but it goes a long way.
The principle is to take an antibody that will recognize something on the surface of the tumor cells
This antibody will bind to a protein and these antibodies will graft chemotherapy onto the cells. »
“This new treatment technique is a bit like the Trojan horse of chemotherapy.”
“Breast cancer is the standard of this Trojan horse but it will grow in all cancers”
“The target of the antibody is HER2. »
“This is the biggest breakthrough in the history of breast cancer.” It halves the risk of progression as well as a 37% decrease in the risk of death. »
“There was a standing ovation. This is very rare, the room has risen. This is proof that it is a change of era. This validates the concept that ADCs will revolutionize the field of cancer treatment. »
“The real revolution is that there is no need to have big HER2 expressions. This works not only for tumors that express high levels of HER2 but also low levels. »
“It’s a treatment that’s going to be available for more than half of all breast cancers.” It is much more effective than conventional chemotherapy. However, it is not without toxicity (hair loss, nausea…) that the side effects are similar to those of conventional chemotherapy. »
“It’s not a new drug, it’s a new family of drugs. »
“The CGFL has opened studies with each of these ADCs. »
“We hope to be able to cure more patients with this new family of drugs.” One in two patients can benefit from this molecule. This is one of the main goals of the CGFL. »
“Last year, one in three patients benefited from an innovation. »
“This molecule is already being reimbursed in a niche in some breast cancers.” This allows if the authorities put their nose in it, that in the coming months (by January) it will eventually be accessible (reimbursed). »
“A large Canadian study has shown: Stop radiation therapy after surgery. Basically you are given less toxic treatments without compromising your chances of survival.
With mammography screening, many tumors are discovered very early.
The study showed that when no radiation therapy is given, patients have an acceptable risk of relapse (2%). On the other hand, when you no longer irradiate patients, you no longer produce side effects. »
“We need to de-escalate the use of radiation therapy”